<p>Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model</p>

Abstract

Background: Our previous findings showed that BCc1, a nanoparticle designed based on nanochelating technology, can be considered a new anti-cancer nanoparticle if confirmed by complementary studies. Goal: In the present study, we investigated the effects of the BCc1 nanoparticle alone on some gene expressions influencing the apoptosis pathway, and also the effect of the mixture of BCc1 nanoparticle and doxorubicin on survival. Method: Using an in vitro study, the effects of the BCc1 nanoparticle on Bax, Bcl2, p53, Caspase7 and p21 gene expressions were assessed after a 24-h treatment using real-time PCR in MCF-7 and MEFs; in addition, using an in vivo study, 4T1 tumor-bearing female Balb/c mice were treated with different doses of the BCc1 nanoparticle and doxorubicin alone and together and then their mean and median survival was evaluated. Result: The results showed that the BCc1 nanoparticle increased gene expressions of RB, p53, Caspase7, p21, and Bax and decreased gene expressions of Bcl2 in MCF-7 significantly, but no change was observed in MEFs expressions. The findings revealed that the BCc1 nanoparticle, when used orally, had the highest mean and median survival time. A mixture of a high dose of the BCc1 nanoparticle (1 mg/kg) and a low dose of doxorubicin (0.1 mg/kg) showed synergistic effects on enhanced life span, while doxorubicin dose was prescribed approximately 50 times less than the murine applicable dose (5 mg/kg). Conclusion: Our results demonstrated that the BCc1 nanoparticle not only has the potential to become a novel nanomedicine for cancer therapy, but it can also provide the basis of a new medicine for cancer management when mixed with a lower applicable dose of doxorubicin.

Intracellular Water Lifetime as a Tumor Biomarker to Monitor Doxorubicin Treatment via FFC-Relaxometry in a Breast Cancer Model

“…The animal treatment protocol was approved by the Italian Ministry of Health (authorization number 807/2017-PR). When the tumor reached volumes of around 150-200 mm 3 , the animals were treated three times at 1-day intervals (days 0, 2 and 4) intravenously via the tail vein at a dose of 5 mg/kg of doxorubicin (26)(27)(28).…”

A 40 Month Double-Blind, Randomized, Placebo-Controlled Trial on the Effect of BCc1 Nanomedicine on Survival of Metastatic and Non-Metastatic Gastric Cancer Patients

“…This nanomedicine could induce apoptosis and cell arrest in cancer cells as well as their genes expression [19]. In a cancer animal model, it was demonstrated that the mixture of BCc1 nanomedicine and doxorubicin could increase the mean OS of the cancer mice by 48%, where doxorubicin dose was reduced by 50 times [46].…”

<p>BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease</p>

“…[14][15][16][17] In the previous studies, anti-neoplastic effects of BCc1 nanomedicine with iron-chelating property were demonstrated in several experiments. 19,20,47 In the present study, this nanomedicine was tested in animal model of DKD to evaluate its impacts on various biochemical and histopathological parameters of this disease.…”